These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 36970591)

  • 21. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 Nov; 31(11):4456-4465. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
    Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.
    Chen S; Shuangyan T; Shi F; Cai H; Wu Z; Wang L; Ma P; Zhou Y; Mai Q; Wang F; Lai J; Chen X; Chen H; Guo W
    Front Immunol; 2024; 15():1430571. PubMed ID: 39131156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
    Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
    Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
    Front Immunol; 2022; 13():848387. PubMed ID: 35300325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study.
    Li H; Wang J; Zhang G; Kuang D; Li Y; He X; Xing C; Wang Y; Shi M; Han X; Ren J; Duan X
    Front Immunol; 2023; 14():1277329. PubMed ID: 38090566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Wu SJ; Ruan DD; Wu QY; Tang Y; Zhang JH; Cai SL; Zhou YF; Luo JW; Fang ZT
    J Hepatocell Carcinoma; 2023; 10():807-820. PubMed ID: 37292114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
    Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.
    Xiang YJ; Wang K; Yu HM; Li XW; Cheng YQ; Wang WJ; Feng JK; Bo MH; Qin YY; Zheng YT; Shan YF; Zhou LP; Zhai J; Cheng SQ
    Hepatol Res; 2022 Aug; 52(8):721-729. PubMed ID: 35536197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Wang L; Lin L; Zhou W
    Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.
    Wang WJ; Liu ZH; Wang K; Yu HM; Cheng YQ; Xiang YJ; Feng JK; Zhou LP; Zhou HK; Pan WW; Guo WX; Shi J; Cheng SQ
    Cancer Med; 2023 May; 12(10):11513-11524. PubMed ID: 36999793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C
    Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
    Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
    Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.